Stock Price & Analysis

Based on the provided data and current market conditions, here's a concise analysis of ABBV:

Technical Analysis The stock is currently showing bearish signals with RSI at 40.07 indicating a slightly oversold condition. The stock closed at $171.56 on Friday, below its 20-day SMA of $176.62, suggesting near-term weakness. The MACD reading of -1.20 confirms the bearish momentum.

Fundamental Strength ABBV maintains strong market positioning with several positive catalysts:

• Skyrizi and Rinvoq continue gaining momentum across multiple indications
• Strong performance in oncology and immunology segments
• Solid pipeline development despite recent setback with emraclidine

Recent Developments

• Expanded collaboration with AbCellera for T-cell engagers in oncology
• Strategic partnership with Simcere Zaiming worth potential $1.055B in milestone payments
• Recent acquisition of Aliada Therapeutics for $1.4B strengthening Alzheimer's pipeline

Market Sentiment Recent analyst ratings show mixed but generally positive sentiment:

• Truist maintains Strong Buy with $211 PT (18.66% upside)
• Piper Sandler raised PT to $220 (26.09% upside)
• Morgan Stanley maintains Buy with $224 PT (30.02% upside)

Conclusion SELL. Despite strong fundamentals and positive analyst sentiment, technical indicators suggest near-term weakness. The stock is trading below key moving averages with bearish momentum. Investors may want to wait for better entry points or technical improvement before establishing new positions.

Based on the available data and market analysis, here is the price prediction for ABBV stock in 2025:

ABBV is expected to reach $195-200 by end of 2025, representing approximately 15% upside from current levels ($171.56). This projection is supported by strong growth in immunology drugs Skyrizi and Rinvoq, which are expected to exceed $27 billion in annual sales by 2027, offsetting Humira revenue decline. Recent acquisitions in neuroscience and oncology segments provide additional growth catalysts.

The technical indicators show ABBV is currently at support levels around $170, with RSI at 40.07 indicating neutral-oversold conditions, suggesting potential for upward movement from current prices.

The S1 support level for ABBV Stock is $169.12 ,The R1 resistant level for ABBV Stock is $176.7.

As of the end of day on 2025-01-24, the price of ABBV Stock was $170.02.

The target price for ABBV Stock according to analyst rating is 203.24, with the highest price target at 240.00 and the lowest at 165.00. Analysts have a Moderate Buy rating on ABBV Stock overall.

The market cap of ABBV is $300.9B.

Based on the provided data and recent market analysis, here is a comprehensive evaluation of ABBV's valuation:

Valuation Analysis ABBV currently shows elevated valuation metrics with a PE ratio of 68.9 in Q3 2024, significantly higher than previous quarters (54.2 in Q1 and 57.4 in Q2). The EV/EBITDA ratio has also increased to 17.2 in Q3 from 15.2 in Q1 2024, suggesting the stock is trading at premium multiples.

Growth & Profitability Despite high valuation metrics, ABBV demonstrates solid operational performance with:

• Revenue growth from $12.3B in Q1 to $14.4B in Q3 2024
• Net income improvement from $1.36B to $1.55B
• Consistent gross margins around 70%

Analyst Sentiment Recent analyst actions indicate mixed but generally positive sentiment:

• Truist Securities maintains Strong Buy with $211 target (Jan 8, 2025)
• Piper Sandler raised target to $220 (Dec 17, 2024)
• B of A Securities initiated at Hold with $191 target (Dec 10, 2024)

Conclusion ABBV appears moderately overvalued based on traditional metrics, but this premium valuation is supported by:

1. Strong revenue and earnings growth
2. Robust product pipeline including Skyrizi and Rinvoq
3. Solid dividend yield of 3.14% (Q3 2024)
4. Positive analyst sentiment with majority maintaining Buy ratings

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.

Based on the provided data and market research, here's the price prediction for ABBV stock in 2030:

ABBV is projected to reach $275-285 by 2030, representing approximately 60-65% upside from current levels. This forecast is supported by three key factors:

1. Strong immunology portfolio growth with Skyrizi and Rinvoq expected to generate over $27 billion in annual sales by 2027, effectively replacing Humira revenue loss while providing additional growth runway through the early 2030s.

2. Robust pipeline development and strategic acquisitions including Cerevel Therapeutics and ImmunoGen, which diversifies revenue streams across oncology, aesthetics, and neuroscience segments while maintaining the company's leadership in key therapeutic areas.

3. Consistent operational execution with trailing 12-month revenue of $55 billion, demonstrating the company's ability to navigate patent cliffs while growing core business segments through innovation and strategic M&A.

ABBV has a total of 50000 employees.